4 ms·
Housebrand OTC drugs in particular are the same as the name brand equivalent. There was a Freakonomics episode where they said pharmacists overwhelmingly choose
by scarface74 6y ago
Housebrand OTC drugs in particular are the same as the name brand equivalent. There was a Freakonomics episode where they said pharmacists overwhelmingly choose house brand OTC products.
House brands of any product have to pass the same relevant regulations.
- yourapostasy 6y agoYep, likely because OTC pharma is a tightly-regulated market? However, there are still gaps I haven't found explanations for yet, so I must be misunderstanding how house branding works. For example, house brands have not materially impacted the insulin market [1] even though it is quite regulated to my best understanding. Even when insulin patents expire, there haven't been house brands introduced on more modern formulations [2] [3]. Nor have house brands moved into vaccine production. There is probably much, much more than meets the consumer retail eye to house branding, and I'd love to get an insider's look at the factors and considerations around the decision to roll out a house brand product. [1] https://insulinnation.com/treatment/why-walmart-insulins-arent-the-answer-to-high-insulin-prices/ https://insulinnation.com/treatment/why-walmart-insulins-are... [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955122/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955122/ [3] https://www.pbs.org/newshour/health/insulin-market-shakeup-patients https://www.pbs.org/newshour/health/insulin-market-shakeup-p...
- gamblor956 6y agoEven when insulin patents expire, there haven't been house brands introduced on more modern formulations [2] [3]. Nor have house brands moved into vaccine production. This is because house brands are made by the name brands. In order to maintain their competitive edge for their name brands, they don't offer the modern formulations white label to the stores, and vaccines generally are not permitted by FDA regulations to be sold white-label.
- yourapostasy 6y agoThanks, I didn't know that about vaccines, where can I find out about this? For DT, there is one generic label [1]. I don't see the commonality of the few others that are generic as well [2]. So the FDA regulation will be interesting to see. Combined with the daunting financing challenges with vaccines [3], that might explain why there are no white label vaccines? In a couple of my previous links, some of the more modern formulations like Humalog came off of patent protection in the US around 2017, but no one outside the manufacturer has picked up white label manufacturing. A lot of times house branding just seems like market segmentation to me based around packaging when the original manufacturer is making the same product, but many times I've picked up a house brand and a name brand packaged food for example, and find sugar is higher up in the ingredients list in the house brand (and the nutritional panel reveals it is a significant ranking change). Thus house brands seem like an obfuscation of the market to my uninformed eye so far. They seem to act in the macro scale as a way to prevent real competitors from arising and taking away real revenue and margin, by stuffing the distribution channel with SKU's that give a slightly larger cut to the distributors in exchange for maintaining the same vendor count (thereby making it much more difficult for a competitor to gain shelf space). Those incentives probably all change around with an ecommerce site like Amazon. I just find this aspect of free markets fascinating as a layperson. [1] https://www.cdc.gov/vaccines/vpd/dtap-tdap-td/hcp/about-vaccine.html https://www.cdc.gov/vaccines/vpd/dtap-tdap-td/hcp/about-vacc... [2] https://www.cdc.gov/vaccines/vpd/vaccines-list.html https://www.cdc.gov/vaccines/vpd/vaccines-list.html [3] https://www.ncbi.nlm.nih.gov/books/NBK221811/ https://www.ncbi.nlm.nih.gov/books/NBK221811/
- gamblor956 6y agosome of the more modern formulations like Humalog came off of patent protection in the US around 2017, but no one outside the manufacturer has picked up white label manufacturing. For drugs, generics still need to prove that their own product meets safety standards and is the equivalent to the drug coming off patent protection. It's not cheap. For biologics like insulin, it's even more expensive. Thus house brands seem like an obfuscation of the market to my uninformed eye so far. They seem to act in the macro scale as a way to prevent real competitors from arising and taking away real revenue and margin, by stuffing the distribution channel with SKU's that give a slightly larger cut to the distributors in exchange for maintaining the same vendor count (thereby making it much more difficult for a competitor to gain shelf space). That's not how retail works. Stores are more than happy to put new products on the shelf, especially if they sell well. They don't "maintain vendor count," they allocate shelf space based on actual sales. If a product doesn't sell well, it loses space to better-selling products on a daily or weekly basis (depending on the store). New products show up all the time, and depending on the arrangement with the manufacturer have between a week and a month to show their selling power. (New products are usually on a consignment basis so the manufacturer only gets paid if units sell.)